AstraZeneca Plc and Merck & Co Inc said on Monday their treatment for newly diag...
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid
The treatment showed a statistically significant and clinically meaningful improvement in progression-free survival in women with newly diagnosed advanced ovarian cancer, the companies said. The combination also improved progression-free survival to a median of 22.1 months compared to 16.6 months for those treated with bevacizumab alone, the companies said.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Separate GSK, AstraZeneca trial results may widen ovarian cancer drug useGlaxoSmithKline and AstraZeneca both reported trial results that will likely mak...
Consulte Mais informação »
Results of GSK and AstraZeneca trials may widen ovarian cancer drug useGlaxoSmithKline and AstraZeneca both reported trial results that will likely mak...
Consulte Mais informação »
I went through menopause before I turned 40: What women should know'And after the hysterectomy I was in full-on menopause with hot flashes, moods swings and weight gain.'
Consulte Mais informação »
Novartis says Kisqali boosts survival in breast cancer patientsNovartis said on Sunday that Kisqali helped women with advanced breast cancer af...
Consulte Mais informação »
Bristol-Myers immunotherapy combo outperforms chemo in lung cancer survival: studyAbout 40% of patients who received a combination of Bristol-Myers Squibb Co&039...
Consulte Mais informação »
Free Apps & Extensions That Improve Productivity & LearningFind out how to make any curriculum more accessible and engaging through the use of learning tools for Chromebooks, iPads, Windows, and Macs
Consulte Mais informação »